Page 925, column 1, section 2.3.1.1, lines 6-12.
The author has alerted us to the following error:
Page 925, column 1, section 2.3.1.1, lines 6-12.
The sentence that previously read:
'At a median follow-up of 2.1 months, dinutuximab recipients (n = 113 intent to treat) had significantly higher EFS rates (66 vs. 46 %; p = 0.01) and overall survival (OS) rates (86 vs. 75 %; p = 0.02) compared with standard therapy recipients (n = 113 intent to treat) in a randomized, open-label, phase III study (NCT00026312; ANBL0032).' should read:
'At a median follow-up of 2.1 years, dinutuximab recipients (n = 113 intent to treat) had significantly higher EFS rates (66 vs. 46 %; p = 0.01) and overall survival (OS) rates (86 vs. 75 %; p = 0.02) compared with standard therapy recipients (n = 113 intent to treat) in a randomized, open-label, phase III study (NCT00026312; ANBL0032).'
The online version of the original article can be found under doi:10.1007/s40265-015-0399-5.
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